secwatch.observer — SEC 8-K summary
======================================

Issuer:     DYADIC INTERNATIONAL INC (DYAI)
CIK:        0001213809
Form:       8-K
Filed at:   2024-05-14T23:59:59+00:00
Accession:  0001437749-24-016675
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Dyadic Q1 2024 net loss $2.01M ($0.07/share), revenue $335K; cash $12.1M; Phase 1 COVID booster successful
--------------------------------------------------------------------------------

- Net loss $2.01M ($0.07 per share) vs $0.956M ($0.03) in Q1 2023; revenue down to $335K from $934K.
- Cash and securities $12.1M as of Mar 31, 2024, up from $7.3M at Dec 31, 2023.
- Phase 1 trial of DYAI-100 COVID booster completed; met safety and antibody response endpoints.
- Issued $6.0M convertible notes (8%, due 2027) on Mar 8, 2024; appointed Patrick Lucy Chairman and Joe Hazelton COO.
- Multiple collaborations with top pharma, ViroVax for H5N1 vaccine, and other partnerships.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1213809/000143774924016675/0001437749-24-016675-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1213809/000143774924016675/dyai20240120_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-016675

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer